B
Bullisch
Bullisch · 25%LXRX
$2.20
Szenariopreis
$1.490
-0.067 (-4.49%)Zum Schluss
Loading chart…
- Hoch
- 1.590
- Eröffnung
- 1.560
- Volumengewichteter Durchschnittskurs
- 1.52
- Volumen
- 1.32M
- Marktkap.
- 629.00M
- Tief
- 1.480
- Umsatz
- 2.01M
- EV/EBITDA, TTM
- -1.10
Lexicon Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is engaged in research and development of drug candidates and the commercialization of the drug, INPEFA (sotagliflozin). INPEFA reduces the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease (CKD), and other cardiovascular risk factors. Sotagliflozin is an orally delivered small molecule drug candidate as a treatment for hypertrophic cardiomyopathy (HCM) and conducts the SONATA-HCM pivotal Phase 3 clinical trial of sotagliflozin in that indication. The Company develops pilavapadin, an orally delivered small molecule drug candidate, as a treatment for neuropathic pain. The Company also develops LX9851, an orally delivered small molecule drug candidate, for the treatment of obesity and associated cardiometabolic disorders.
KI-Analyse of Lexicon Pharmaceuticals Inc (LXRX)
HaltenLexicon Pharmaceuticals Inc (LXRX) is currently trading at $1.52, which is significantly below the analyst price target of $8, indicating a potential upside of over 400%. However, the stock has a very low RSI of 19.53, suggesting it is oversold, but it has also experienced a 25.85% decline over the past 20 days, indicating bearish momentum. The main risk is the company's negative earnings trend, with a net income loss of $31.77 million reported in Q2 2026, which raises concerns about its financial stability.
Analystenbewertungen (7)
+170.47% Aufwärtspotenzial
Kaufen
4 Kaufen
3 Halten
0 Verkaufen
Aktuell: 1.49
Tief
2.10
Durchschnitt
4.03
Hoch
6.00
Cantor Fitzgerald
Übergewichten
$8
2026-09-28
Cantor Fitzgerald
2026-09-28
Kursziel
$8
Übergewichten
Citi
Kaufen
—
2026-05-11
Citi
2026-05-11
Kursziel
—
Kaufen
Citi
Kaufen
—
2026-03-10
Citi
2026-03-10
Kursziel
—
Kaufen
H.C. Wainwright
Kaufen
$6
2026-03-05
H.C. Wainwright
2026-03-05
Kursziel
$6
Kaufen
Citi
Kaufen
—
2025-08-07
Citi
2025-08-07
Kursziel
—
Kaufen
Bewertungskennzahlen
Das aktuelle erwartete KGV von Lexicon Pharmaceuticals Inc (LXRX) beträgt 0.00, verglichen mit dem 5-Jahres-Durchschnitt von -3.16.
Alphio-AI-Kursszenarien für LXRX
Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.
Whales, die LXRX halten
Event-Zeitleiste
News
9.010-21NewsfilterSotagliflozin Shows Positive Effects on Cardiac Function in Hypertrophic Cardiomyopathy
6.009-28FoolAnalyst Initiates Bullish Coverage on Lexicon Pharmaceuticals
6.009-28NASDAQ.COMAnalyst Bullish on Lexicon Pharmaceuticals' Prospects
9.008-31NASDAQ.COMLexicon Pharmaceuticals Reports New Sotagliflozin Data from SOLOIST-WHF Trial
- 9.008-31Newsfilter
Lexicon's Drug Shows Efficacy in Heart Failure Patients
LXRX FAQ – beantwortet von Alphio AI
Lexicon Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is engaged in research and development of drug candidates and the commercialization of the drug, INPEFA (sotagliflozin). INPEFA reduces the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease (CKD), and other cardiovascular risk factors. Sotagliflozin is an orally delivered small molecule drug candidate as a treatment for hypertrophic cardiomyopathy (HCM) and conducts the SONATA-HCM pivotal Phase 3 clinical trial of sotagliflozin in that indication. The Company develops pilavapadin, an orally delivered small molecule drug candidate, as a treatment for neuropathic pain. The Company also develops LX9851, an orally delivered small molecule drug candidate, for the treatment of obesity and associated cardiometabolic disorders. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Lexicon Pharmaceuticals Inc (LXRX) is currently trading at $1.52, which is significantly below the analyst price target of $8, indicating a potential upside of over 400%. However, the stock has a very low RSI of 19.53, suggesting it is oversold, but it has also experienced a 25.85% decline over the past 20 days, indicating bearish momentum. The main risk is the company's negative earnings trend, with a net income loss of $31.77 million reported in Q2 2026, which raises concerns about its financial stability.
7 analysts cover LXRX: 4 rate it Buy, 3 Hold and 0 Sell. The average price target is 4.03.
Community
Mehr ↗Noch keine Beiträge
Registriere dich oder melde dich an, um mitzudiskutierenDiese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.